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Abstract Background. The reverse-transcriptase inhibi-
tor lamivudine has in vitro synergy with zidovudine
against the human immunodeficiency virus (HIV). We
studied the activity and safety of lamivudine plus zidovu-
dine as compared with either drug alone as treatment for
patients with HIV infection, most of whom had not previ-
ously received zidovudine.
Methods. Three hundred sixty-six patients with 200
to 500 CD4 cells per cubic millimeter who had received
zidovudine for four weeks or less were randomly as-
signed to treatment with one of four regimens: 300 mg of
lamivudine every 12 hours; 200 mg of zidovudine every
8 hours; 150 mg of lamivudine every 12 hours plus zido-
vudine; or 300 mg of lamivudine every 12 hours plus zi-
dovudine. The study was double-blind and lasted 24
weeks, with an extension phase for another 28 weeks.
Results. Over the 24-week period, the low-dose and
high-dose regimens combining lamivudine and zido-
vudine were associated with greater increases in the
CD4 cell count (P0.002 and P0.015, respectively)
and the percentage of CD4 cells (P0.001 for both)
and with greater decreases in plasma levels of HIV type
1 (HIV-1) RNA (P0.001 for both) than was treatment
with zidovudine alone. Combination therapy was also
more effective than lamivudine alone in lowering plas-
ma HIV-1 RNA levels and increasing the percentage of
CD4 cells (P0.001 for all comparisons), and these ad-
vantages persisted through 52 weeks. Adverse events
were no more frequent with combination therapy than
with zidovudine alone.
Conclusions. In HIV-infected patients with little or no
prior antiretroviral therapy, treatment with a combination
of lamivudine and zidovudine is well tolerated over a one-
year period and produces more improvement in immuno-
logic and virologic measures than does treatment with ei-
ther agent alone. (N Engl J Med 1995;333:1662-9.)
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ZIDOVUDINE is the recommended initial therapyfor human immunodeficiency virus (HIV) in-
fection1 and is generally tolerated well.2 However, clin-
ical studies indicate that its beneficial effects are limit-
ed in duration,3 partly because of the development of
resistance by HIV.4,5 Combination therapy with antiret-
roviral agents may have more sustained antiviral ef-
fects, decrease the emergence of drug resistance, and
affect a wider range of cellular or tissue reservoirs of
HIV infection.6 Studies evaluating treatment with a
combination of two reverse-transcriptase inhibitors
have found favorable effects on CD4 counts and plas-
ma viremia.7-9 Even in early, asymptomatic disease, there
is substantial ongoing replication of HIV type 1 (HIV-
1),10-12 and turnover both of HIV-1 in plasma and of
HIV-1–producing cells is generally high, with a half-
life on the order of two days.13,14 There is a need for po-
tent, safe antiretroviral therapy, which may be achieved
by using agents in combination.
Lamivudine, or ()-2-deoxy-3-thiacytidine (also
known as 3TC), a reverse-transcriptase inhibitor, has
in vitro activity against a range of isolates of HIV-1, in-
cluding virus resistant to zidovudine.15-17 Lamivudine
and zidovudine are synergistic in vitro.18 A mutation in
the HIV-1 polymerase gene at codon 184 that is select-
ed when lamivudine is present confers resistance to
that drug.19-21 Viruses with this mutation remain sensi-
tive to zidovudine.19,20 The in vitro introduction of the
mutation into virions containing mutations that confer
resistance to zidovudine resensitizes those viruses to
zidovudine.19 In phase 1 studies lamivudine has had
high oral bioavailability and is well tolerated.22,23 We
studied two doses of lamivudine in combination with
zidovudine in patients with little or no prior antiretro-




Patients were found to be seropositive for HIV-1 by a standard en-
zyme-linked immunosorbent assay, with confirmation by the Western
blot assay. Eligible patients had received zidovudine for four weeks or
less, were 12 or more years of age, had Karnofsky scores of 60 or
above, and had 200 to 500 CD4 cells per cubic millimeter. The cri-
teria for exclusion from the study included results of liver-function
tests more than five times the upper limit of the normal range, an ab-
solute neutrophil count below 1000 cells per cubic millimeter, a hemo-
globin level below 9.2 g per deciliter for male patients or below 8.8 g
per deciliter for female patients, a positive serum pregnancy test for
female patients, prior therapy with antiretroviral drugs other than zi-
dovudine, and active opportunistic infections or cancers requiring sys-
temic therapy. Patients who had had an illness considered to define
the presence of the acquired immunodeficiency syndrome (AIDS) but
who no longer required therapy for the acute illness were allowed to
enroll in the study.
Study Design and Treatment Regimens
The study was a double-blind, randomized, multicenter, place-
bo-controlled trial lasting 24 weeks, with a blinded extension
phase for an additional 28 weeks, conducted at 26 sites in North
America. Approval was obtained from the investigational review
board at each institution, and the patients gave written informed
consent.
Patients were randomly assigned to receive one of four oral treat-
ments: 200 mg of zidovudine (Retrovir, Glaxo Wellcome, Research
Triangle Park, N.C.) every 8 hours plus placebo resembling lamivu-
dine (the zidovudine-only group); 300 mg of lamivudine (Epivir,
Glaxo Wellcome) every 12 hours plus placebo resembling zidovu-
dine (the lamivudine-only group); 150 mg of lamivudine every 12
hours plus 200 mg of zidovudine every 8 hours (the low-dose com-
bined-therapy group); or 300 mg of lamivudine every 12 hours plus
200 mg of zidovudine every 8 hours (the high-dose combined-ther-
apy group).
Adverse events were managed in accordance with predetermined
guidelines, and the severity of the events was graded according to the
criteria of the AIDS Clinical Trials Group.24
Evaluation of Patients
Patients were seen during the screening period, at randomization,
and at week 2, week 4, and every four weeks thereafter. A full history
was taken, and a physical examination performed, at the time of
screening and at weeks 24 and 52. At each vis-
it medications were reviewed and vital signs,
Karnofsky scores, and results of laboratory
tests of safety were obtained. All female
patients had pelvic examinations and Pap
smears at the start of the study and at weeks
24 and 52 to evaluate the progression of pos-
sible cervical disease. All laboratory studies
were performed by Roche Biomedical Labo-
ratories (Research Triangle Park, N.C., and
Raritan, N. J.).
Assessments were also made when a pa-
tient discontinued the use of the study drug
and four weeks later. Patients who discontin-
ued the study drug were requested to return
for CD4 cell counts every four weeks through
week 24.
Measures of HIV-1 Disease
The measures of HIV-1 disease used in
the study included assays of T-lymphocyte
subgroups, reverse-transcriptase polymerase-
chain-reaction (PCR) assays for HIV-1 RNA
in plasma (Roche), the immune-complex–dis-
sociated HIV p24 antigen assay (Coulter, Hi-
aleah, Fla.), and assays for b2-microglobulin
and neopterin. The threshold level of detec-
tion for HIV-1 RNA was 200 copies per mil-
liliter. Lower values were recorded as 200
copies per milliliter. The primary outcome
measures evaluated were changes from base
line in levels of HIV-1 RNA and CD4 cell
counts in the treatment groups.
Statistical Analysis
The patients were randomly assigned to
the four treatment groups in equal numbers
at each participating center with the use of
permuted blocks. A summary measure25 was
used to characterize the profile of HIV dis-
ease markers over the first 24 weeks of the
study. The time-weighted area under the
curve (as calculated by the trapezoidal rule)
minus the base-line value was used to com-
pare the groups with respect to the data col-
lected over time during the first 24 weeks of
the study. For patients who completed the 52
weeks of the study, the average of the last
three evaluations (at weeks 44, 48, and 52)
minus the base-line value was used as a sum-
mary measure in comparing the groups with
respect to the durability of the treatment effect. The summary
measures were compared by the van Elteren test,26 an extension of
the Wilcoxon two-sample test that permits stratified analyses, after
stratification according to study site. Primary pairwise comparisons
between each treatment group and the zidovudine-only group were
adjusted with use of the Bonferroni correction for multiple compar-
isons. All P values were two-sided.
A secondary analysis among the patients who had 20,000 or more
copies of HIV-1 RNA per milliliter at base line used the reverse-
transcriptase PCR assay to compare the proportions who had a re-
duction by 2 log from the base-line value in at least one measurement
made at week 2, 4, 8, 12, 16, 20, or 24; this analysis used the method
of Wei and Johnson.27 A similar analysis was used to compare the
proportions of patients with a reduction of 50 percent from base line
on the immune-complex–dissociated p24 antigen assay. Exact tests
were used to compare the groups with respect to the incidence of ad-
verse events during as many as 30 days after permanent discontinu-
ation of the study drug. The patients’ base-line characteristics were
compared by a Cochran–Mantel–Haenszel test after stratification
according to study site, or by the van Elteren test after the same strat-
ification. The times to the permanent discontinuation of the study
*Plus–minus values are means SE. ICD denotes immune-complex–dissociated. Because of rounding, percentages do
not all total 100.
†By the van Elteren test, with control for the study site.
‡By the Cochran–Mantel–Haenszel test, with control for the study site.
§By an exact test.
¶Reasons include noncompliance and the decision of the patient or the investigator not to continue the drug.
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Median age — yr 34.0 34.4 33.9 33.9 0.855†












Race or ethnic group — % of 
patients
0.938‡
White 61 60 64 59
Black 16 18 16 15
Hispanic 20 22 18 24
Other 2 0 1 2
CD4 cells
No./mm3
Mean 34911.4 34012.8 36611.8 38011.5 0.109†
Median 336 332 360 372
Percent of all lymphocytes
Mean 20.70.8 20.70.7 21.00.7 21.60.6 0.441†
Median 19.3 19.6 21.3 21.8
Positive ICD p24 antigen
assay — % of patients
40 34 33 26 0.157§
HIV RNA
No. of patients 90 80 88 93
Mean no. of copies/ml 87,500 79,200 87,100 80,800
Median no. of copies/ml 45,500 41,400 25,900 33,200
Mean log copies/ml 4.60.1 4.50.1 4.40.1 4.40.1 0.387†
No. of patients with 
20,000 copies/ml 
63 54 49 58 0.251§
Asymptomatic — % of 
patients
74 73 68 76 0.265‡
Discontinued study drug 
early — no. of
patients (%) 
25 (27) 19 (22) 23 (25) 24 (26) 0.887§
Adverse events 11 6 8 4 0.278§
New AIDS-defining 
illness
1 0 0 0
Causing withdrawal 
from study
2 1 1 1
Other 8 5 7 3
Lost to follow-up 11 7 10 13 0.677§
Other reasons for 
discontinuation¶
3 6 5 7
drug and the times to the first severe or life-
threatening laboratory abnormality or clinical
adverse event as defined in the protocol were
plotted with Kaplan–Meier curves and com-
pared by the log-rank test. All the analyses of
efficacy were performed on an intention-to-
treat basis.
Four scheduled interim evaluations of the
safety data were reviewed by an independent
Data and Safety Monitoring Board. The study
data were analyzed as planned after the last





A total of 366 patients were ran-
domly assigned to the four treatment
groups. The groups were well bal-
anced with respect to demographic
variables (Table 1). Thirteen percent
of the patients were female, and 39
percent belonged to minority groups.
Base-line characteristics of HIV-1
disease were similar among the four
groups (Table 1). From 11 to 20 per-
cent of the patients in each group
had previously received antiretrovi-
ral therapy (zidovudine only), and
the median duration of that therapy
in the four groups was three weeks
or less (P0.22).
Among the 366 patients initially randomized, 275 (75
percent) were still receiving the study medication at
week 24 (Table 1). Kaplan–Meier plots of the time to the
permanent discontinuation of the study drug revealed no
significant difference among treatment groups in rates of
discontinuation over the 52-week period (P0.76; data
not shown). Eleven percent of the patients initially ran-
domized were lost to follow-up (Table 1).
There were no significant differences between the
patients who completed the 24-week study period and
those who did not with respect to age, sex, the absolute
CD4 count, the percentage of CD4 cells, or the
HIV-1 RNA concentration (data not shown). Nor did
the median absolute CD4 count and the log concen-
tration of HIV-1 RNA at base line differ statistically
within each treatment group between the patients who
completed 24 weeks of the study and those who did not
(data not shown).
Immunologic and Virologic Effects
Immunologic Activity
The median time-weighted increases from base line
in the absolute CD4 count during the first 24 weeks of
the study are shown in Table 2. The differences between
the zidovudine-only group and each of the combina-
tion-therapy groups were significant. When the change
in the absolute CD4 count in the lamivudine-only
group was compared with the change in each combina-
tion-therapy group, the differences were not statistical-
ly significant. There was no statistically significant dif-
ference between the two combination-therapy groups or
between the two monotherapy groups.
The greatest mean (SE) change in the absolute
CD4 count was 3214 cells per cubic millimeter in
the zidovudine-only group, 3311 cells per cubic milli-
meter in the lamivudine-only group, 7017 cells per
cubic millimeter in the low-dose combination-therapy
group, and 6516 cells per cubic millimeter in the
high-dose combination-therapy group. At 24 weeks, the
mean change from base line in the CD4 count was
1414 cells per cubic millimeter in the zidovudine-only
group, 1013 cells per cubic millimeter in the lamivu-
dine-only group, 4017 cells per cubic millimeter in
the low-dose combination-therapy group, and 5816
cells per cubic millimeter in the high-dose combination-
therapy group (Fig. 1).
At week 52, data from 45 to 55 percent of the pa-
tients in each group were available for analysis, partly
because some patients had not completed the extension
phase by the time of the analysis. Among the patients
who could be studied, the mean increases in the CD4
count at week 52 were 6122 and 6023 cells per cu-
bic millimeter in the low-dose and high-dose combina-
tion-therapy groups, respectively. At 52 weeks the zido-
vudine-only group had a mean decrease of 5314 cells
per cubic millimeter in the CD4 count, resulting in a
difference of approximately 114 cells per cubic millime-
ter between that group and either combination-therapy
*Means and medians shown are the changes from base line in the time-weighted area under the curve for the measure
indicated during the 24 weeks of the study. Positive numbers denote increases, and negative numbers decreases. Plus–minus
values are means SE.
†Numbers shown are the numbers of patients for whom values were obtained at randomization and at least twice during
the study and who were included in the analysis.
‡By primary pairwise comparison of the median values shown, with use of the van Elteren test with control for study site.
§This P value was significant after the use of the Bonferroni correction for multiple comparisons (adjusted level of sig-
nificance, 0.05	3, or 0.017).
¶By secondary pairwise comparison of the median values shown, with use of the van Elteren test with control for study site.
Table 2. Time-Weighted Changes from Base Line in Immunologic and Virologic End






LOW DOSE HIGH DOSE
Primary
Absolute change in CD4 count
No. of patients† 85 80 85 85
Mean no. of cells/mm3 16.69.4 23.77.4 54.911.3 44.98.6
Median no. of cells/mm3 11.9 24.0 66.3 41.3
P value (vs. zidovudine only)‡ — 0.52 0.002§ 0.015§
P value (vs. lamivudine only)¶ — — 0.025 0.061
Change in log HIV RNA
No. of patients† 86 77 80 88
Mean no. of copies/ml 0.310.03 0.590.04 1.120.07 1.150.07
Median no. of copies/ml 0.31 0.60 1.20 1.10
P value (vs. zidovudine only)‡ — 0.001§ 0.001§ 0.001§
P value (vs. lamivudine only)¶ — — 0.001§ 0.001§
Secondary
Change in CD4 as a percentage
of all lymphocytes
No. of patients† 85 81 83 85
Mean % change 1.60.3 1.50.3 3.60.4 4.20.4
Median % change 2.0 1.1 3.2 4.2
P value (vs. zidovudine only)‡ — 0.12 0.001§ 0.001§
P value (vs. lamivudine only)¶ — — 0.001§ 0.001§
group (Fig. 1). When we assessed the durability of the
response, both combination-therapy groups had a more
sustained increase in the absolute CD4 cell count
than the zidovudine-only group (Table 3). The chang-
es from base line in the percentage of CD4 cells
(among all lymphocytes) followed a pattern similar to
that of the changes in the absolute CD4 count (Ta-
bles 2 and 3).
Antiretroviral Activity
The median 24-week time-weighted change from
base line in the plasma concentration of HIV-1 RNA
was a decrease of 50 percent in the zidovudine-only
group and of 75 percent in the lamivudine-only
group, whereas there were decreases of 94 and 92
percent in the low-dose and high-dose combination-
therapy groups, respectively (Table 2). The differences
between the combination-therapy groups and the mono-
therapy groups were significant, but the difference be-
tween the two combination-therapy groups was not.
The effect of lamivudine monotherapy was significant-
ly greater than that of zidovudine monotherapy over
the first 24 weeks, primarily because of a greater initial
reduction in the viral load. The greatest mean reduc-
tions in the plasma concentration of HIV-1 RNA were
0.520.04 log in the zidovudine-only group, 1.190.07
log in the lamivudine-only group, 1.560.10 log in the
low-dose combination-therapy group, and 1.550.09
log in the high-dose combination-therapy group. At
week 24, the mean decrease was 0.250.06 log in the
zidovudine-only group, 0.420.05 log in the lamivu-
dine-only group, 0.900.09 log in the low-dose combi-
nation-therapy group, and 0.990.09 log in the high-
dose combination-therapy group (Fig. 2).
There were significantly greater sustained reductions
in HIV-1 RNA concentrations in both combination-
therapy groups over the 52-week period than in either
monotherapy group (Table 3). There was no significant
difference in effect between the combination-therapy
groups or between the monotherapy groups.
In a subgroup of 224 patients who began the study
with 20,000 or more copies of HIV-1 RNA per millili-
ter, the maximal mean decreases in HIV-1 RNA were
0.55 log (median, 0.60) in the zidovudine-only group
and 1.18 log (median, 1.37) in the lamivudine-only
group. The maximal mean decreases were 1.87 log (me-
Figure 1. Mean (SE) Changes from Base Line in Absolute CD4 Counts, According to the Week of the Study.
The number of patients shown for each week in each treatment group is the number who could be evaluated at that time. After week
24, the numbers of patients indicate the numbers available for study at each point in the analysis; the numbers do not indicate rates
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PATIENTS WHO COULD BE EVALUATED
dian, 2.11) in the low-dose combination-therapy group
and 1.88 log (median, 2.06) in the high-dose combina-
tion-therapy group, a reduction of 99 percent. The per-
centage of patients with at least one HIV-1 RNA meas-
urement during treatment that showed a reduction of
2 log or more was higher in the combined-therapy
groups than in either monotherapy group (2 percent of
patients receiving zidovudine only, 9 percent of those
receiving lamivudine only, 61 percent of those receiving
low-dose combination therapy, and 69 percent of those
receiving high-dose combination therapy; P0.001 for
the comparison of low-dose combination therapy with
zidovudine monotherapy).
In general, comparisons of the 24-week time-weight-
ed average levels of neopterin and b2-microglobulin ob-
tained with zidovudine monotherapy and either dose of
combination therapy favored the combination therapy
(data not shown). Among the patients whose levels of
immune-complex–dissociated p24 antigen at random-
ization were at least double the lower limit of the assay,
the proportion who had at least a 50 percent reduction
in p24 antigen was significantly higher in the low-dose
combination-therapy group (63 percent) than in the zi-
dovudine-only group (32 percent, P0.011).
Safety
The median follow-up in the treatment groups
ranged from 320 to 364 days. The percentages of pa-
tients who had serious adverse events attributed to any
cause or who were withdrawn from the study because
of adverse events are shown in Ta-
ble 4. Serious adverse events did not
occur more often in any one organ
system than in the others (data not
shown). There were no significant
differences among treatment groups
in the time to the first adverse event
(P0.217 by the log-rank test). How-
ever, adverse events occurred more
rapidly in the three groups receiv-
ing zidovudine than in the lamivu-
dine-only group (P0.044). There
were three non–drug-related deaths
during the study.
The clinical adverse events attrib-
uted to study drugs were most com-
monly gastrointestinal effects, usu-
ally nausea, and were more frequent
in the three groups receiving zido-
vudine (P0.06 for all gastrointesti-
nal events, and P0.001 for nau-
sea). Of 29 patients withdrawn from
the study during the first 24 weeks
because of clinical adverse events,
14 were withdrawn because of gas-
trointestinal side effects and 9 were
withdrawn because of malaise and
fatigue.
Neurologic adverse events, pre-
dominantly headache, were the sec-
ond most common class of events attributed to the
study drugs, and they were distributed evenly among
treatment groups. Peripheral neuropathy was usually
mild; two patients in the zidovudine-only group and
one in the lamivudine-only group required an interrup-
tion of the dose, with only one permanent withdrawal.
There were no withdrawals due to pancreatitis.
Two patients were withdrawn because of anemia,
one in the zidovudine-only group and one in the low-
dose combination-therapy group. Nineteen patients
(5 percent), none of whom received lamivudine mono-
therapy, had absolute neutrophil counts below 750
cells per cubic millimeter. No other severe laboratory
abnormality affected more than 5 percent of the study
population. The results of liver-function tests tended to
be mildly elevated; 85 percent of all abnormal alanine
aminotransferase values measured were within five
times the upper limit of normal.
DISCUSSION
The results of this study show the potent antiretrovi-
ral activity of lamivudine in combination with zidovu-
dine in HIV-infected patients with limited or no previ-
ous use of zidovudine. The combinations of lamivudine
and zidovudine resulted in significantly greater and
more sustained decreases in plasma levels of HIV-1
RNA over the 24 weeks of the study than did treatment
with either drug alone. A persistent decrease in plasma
levels of HIV-1 RNA, by 0.8 to 1 log, was observed in
the combination-therapy groups even through week 52.
*Means and medians shown in this analysis were calculated from the average of the values obtained at the last three visits
during the 52-week period for each available patient, minus the base-line value for that patient. Positive numbers denote
increases, and negative numbers decreases. Plus–minus values are means SE.
†By primary pairwise comparison of the median values shown, with use of the van Elteren test with control for study site.
‡This P value was significant after the use of the Bonferroni correction for multiple comparisons (adjusted level of sig-
nificance, 0.05	3, or 0.017).
§By secondary pairwise comparison of the median values shown, with use of the van Elteren test with control for
study site.







LOW DOSE HIGH DOSE
Primary
Absolute change in CD4 count
No. of patients 52 56 50 43
Mean no. of cells/mm3 27.812.0 5.311.0 52.018.4 59.415.0
Median no. of cells/mm3 26.5 5.8 69.4 66.0
P value (vs. zidovudine only)† — 0.35 0.001‡ 0.001‡
P value (vs. lamivudine only)§ — — 0.073 0.02‡
Change in log HIV RNA
No. of patients 38 42 33 36
Mean no. of copies/ml 0.180.07 0.360.07 0.800.11 1.030.10
Median no. of copies/ml 0.20 0.29 0.81 1.00
P value (vs. zidovudine only)† — 0.31 0.001‡ 0.001‡
P value (vs. lamivudine only)§ — — 0.007‡ 0.001‡
Secondary
Change in CD4 as a percentage
of all lymphocytes
No. of patients 52 56 50 43
Mean % change 0.30.6 1.00.4 5.80.8 6.20.7
Median % change 0.4 0.4 5.0 6.2
P value (vs. zidovudine only)† — 0.79 0.001‡ 0.001‡
P value (vs. lamivudine only)§ — — 0.005‡ 0.003‡
When the change in HIV-1 RNA levels was analyzed in
the 224 patients who had base-line levels 2 log or more
above the threshold of detection of the reverse-trans-
criptase PCR assay, the median peak decrease in levels
among patients receiving combination therapy at either
dose was 2.1 log, and approximately two thirds of the
patients in the combination-therapy groups had at least
one value that was 2 log or more below the base-line
value during the study. This double-blind, randomized
clinical trial used changes in plasma levels of HIV-1
RNA as a primary end point. The plasma level of HIV-
1 RNA is a strong predictor of the progression of HIV-
1 infection, independently of the CD4 cell count.28,29
In addition, retrospective analyses of several prospec-
tive clinical trials have shown that a reduction in the
plasma level of HIV-1 RNA in response to therapy is
an independent predictor of clinical benefit.30-32
The decreases in HIV-1 RNA levels were accompa-
nied by substantial increases from the base-line CD4
cell count over the first 24 weeks of the study in patients
who received the combination therapy at either dose, as
compared with zidovudine monotherapy. Unlike many
studies evaluating other therapies,3,7-9,33-36 our study
showed sustained increases from the base-line CD4
cell count with both combination treatments and no re-
turn toward base-line values in patients followed for 52
weeks. The difference between the combination groups
and the zidovudine-only group in the mean increase
from base line at 52 weeks was more than 100 cells per
cubic millimeter. Although conflicting results have been
reported,2 several earlier studies of antiretroviral thera-
py have shown clinical benefit when the therapy being
evaluated produced changes in CD4 cell counts33-36
that were either less substantial or less prolonged than
the changes we observed. Given the greater magnitude
and duration of the effect of treatment combining lami-
vudine and zidovudine on the CD4 cell count and the
viral burden, it is possible that this combination will
Figure 2. Mean (SE) Changes from Base Line in the Log Concentration of HIV RNA, According to the Week of the Study.
The number of patients shown for each week in each treatment group is the number who could be evaluated at that time. After week
24, the numbers of patients indicate the numbers available for study at each point in the analysis; the numbers do not indicate rates
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PATIENTS WHO COULD BE EVALUATED
*The median number of patient-days studied in the analysis was 340.
†By a two-tailed exact test.
‡Includes fatal, life-threatening, disabling, or incapacitating events; events that resulted in hospitalization or prolonged it;
or any congenital anomaly, cancer, or overdose, regardless of the relation attributed to the study drug.
§Regardless of the relation attributed to the study drug. Severe denotes grade III or IV in the toxicity grading scale of
the AIDS Clinical Trials group.












no. of patients (%)
Withdrawal due to adverse event 11 (12) 7 (8) 7 (8) 8 (9) 0.771
Serious adverse event‡ 12 (13) 7 (8) 10 (11) 8 (9) 0.678
Death 2 (2) 1 (1) 0 0 —
Severe clinical toxicity§ 10 (11) 5 (6) 7 (8) 8 (9) 0.687
Severe laboratory toxicity§ 21 (23) 13 (15) 24 (26) 20 (21) 0.32
have a more sustained clinical benefit than those re-
ported previously. However, prospective clinical trials
with sufficient power to detect differences in clinical
end points are needed to substantiate this hypothesis.
Several factors may explain the observed effects of
combined therapy with lamivudine and zidovudine.
Both drugs are potent inhibitors of HIV-1 and act syn-
ergistically against primary clinical isolates in vitro.37
Because the phosphorylation of lamivudine and zido-
vudine differs in resting and activated CD4 lympho-
cytes, they may target different populations of infected
cells.38 The sustained antiviral effect of the combina-
tion may also be due in part to the reduction in the de-
velopment of resistance to zidovudine. In a parallel
study comparing zidovudine monotherapy with the
combination of lamivudine plus zidovudine in previ-
ously untreated patients, mutations confirming resist-
ance to zidovudine appeared more slowly in the pa-
tients treated with the drug combination.39,40 In vitro
selection of the methionine-to-valine mutation at ami-
no acid 184 of the reverse-transcriptase enzyme re-
stores susceptibility to zidovudine in molecular clones
that carry mutations conferring zidovudine resistance.19,40
Thus, interactions between drug-resistance mutations in
the HIV-1 pol gene may contribute to the prolonged ef-
fect of the combined therapy.
The overall effects on plasma levels of HIV-1 RNA
and CD4 cell counts did not differ significantly be-
tween the two monotherapy groups, despite the proba-
bility that lamivudine-resistant variants of HIV-1 would
emerge rapidly in the patients receiving lamivudine
monotherapy.41 Explanations for the observed effect of
this monotherapy are speculative. The mutation confer-
ring resistance to lamivudine does result in an amino
acid change at the active site of the reverse-trans-
criptase enzyme in a motif that is highly conserved
across most retroviruses42 and could result in virions with
impaired replication.43,44
An important finding of this study was the low fre-
quency of serious adverse events in any treatment
group. Lamivudine monotherapy was well tolerated.
Mean hemoglobin levels increased
in patients receiving this therapy
(data not shown), and no episodes
of severe neutropenia were observed.
Adding lamivudine to zidovudine
did not alter the safety profile ob-
served with zidovudine alone. There
were no significant differences in ad-
verse events or immunologic or anti-
viral effects according to the dosage
of combination therapy, and therefore
the low dose should be used in treat-
ment and in further clinical trials.
In summary, treatment combin-
ing lamivudine and zidovudine may
be appropriate as the initial therapy
for asymptomatic HIV-infected pa-
tients who have 200 to 500 CD4
cells per cubic millimeter. This conclusion is based on
the pronounced and durable effect of the combination
treatment, as compared with zidovudine monotherapy,
on virologic and immunologic markers of HIV-1 infec-
tion and on the excellent tolerability of the two drugs
in combination. This conclusion is supported by evi-
dence that asymptomatic patients, in general, have a
high overall burden of HIV-110-12 that is undergoing
rapid turnover.13,14 The early institution of potent com-
bination therapy may be needed to limit viral replica-
tion and delay both the development of resistance to
antiretroviral drugs and the clinical progression of
infection.45 The data from this study show that combi-
nations of lamivudine and zidovudine have a sustained
effect on CD4 cell counts and viral replication in
HIV-1–infected patients.
APPENDIX
In addition to the study authors, the North American HIV Working
Party included B. Akil, G. Beall, N. Bellos, P.S. Berry, C. Brummitt,
B. Cameron, C. Cohen, H. Donabedian, K.H. Mayer, G.F. McKinley,
G.E. Sepulveda, M. Thompson, C. Tsoukas, S. Walmsley, J. Horton,
T. Kerkering, E. Matthew, D. Pearce, D. Peterson, J.C. Pottage, Jr.,
J. Sampson, W.B. Smith, and B. Yangco. The study personnel at the
individual sites were J. Johnson, J. Cowan, C. Kaczka, S.H. Price,
R. Zameck, D. Dawson, B. Pobiner, C. Gilbert, J. Scott-Lennox,
R. Demasi, P. Jarrett, G. Yuen, J. Esinhart, and G. Pakes.
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